Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Summary

DelveInsight’s, “Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2026” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neuromyelitis Optica Spectrum Disorder (NMOSD): Understanding

Neuromyelitis Optica Spectrum Disorder (NMOSD): Overview

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory and demyelinating disorder of the central nervous system that primarily affects the optic nerves, spinal cord, and, in some patients, the brainstem and area postrema. It was historically considered a variant of multiple sclerosis but is now recognized as a distinct autoimmune disorder, largely because of its association with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies. NMOSD commonly manifests as optic neuritis, acute myelitis, area postrema syndrome characterized by unexplained nausea, vomiting or hiccups, and acute brainstem syndromes.

The precise etiology of NMOSD remains unclear; however, genetic susceptibility and autoimmune mechanisms are thought to contribute to disease development. Certain genetic variants, including major histocompatibility complex (MHC) variants such as HLA-DRB1*03:01, have been associated with increased risk. NMOSD may also occur in association with other autoimmune diseases, including systemic lupus erythematosus, Sjögren syndrome, celiac disease, and sarcoidosis. In approximately 20%–30% of cases, an environmental trigger such as infection or vaccination has been reported before an attack.

NMOSD is primarily an autoimmune astrocytopathy mediated by antibodies against aquaporin-4 (AQP4), a water channel highly expressed on astrocytes in regions such as the optic nerves, spinal cord, and area postrema. AQP4-IgG is detected in more than 60%–90% of patients. Binding of these antibodies to AQP4 can trigger perivascular inflammatory and lymphocytic infiltration, complement activation, astrocytic injury, and subsequent axonal damage and demyelination. This preferentially affects the optic nerves, spinal cord, and specific brainstem regions, producing the characteristic neurological manifestations of NMOSD.

Diagnosis of NMOSD is based on the patient's clinical presentation, serological testing for AQP4-IgG, and magnetic resonance imaging (MRI) of the brain and spinal cord, with and without gadolinium. Core clinical characteristics include optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, and certain diencephalic or cerebral syndromes. MRI may demonstrate longitudinally extensive spinal cord lesions extending over three or more vertebral segments, optic nerve lesions or enhancement, and characteristic brain or area postrema lesions. AQP4-IgG testing is particularly important for distinguishing NMOSD from other demyelinating disorders such as multiple sclerosis and MOG antibody-associated disease.

Treatment of NMOSD focuses on controlling acute attacks and preventing future relapses and neurological disability. Acute attacks are generally treated with high-dose intravenous corticosteroids, such as methylprednisolone, while plasmapheresis or intravenous immunoglobulin may be used in appropriate cases. Because NMOSD frequently follows a relapsing course, long-term immunosuppressive therapy is used to reduce the risk of further attacks; traditional options include azathioprine, rituximab, mycophenolate, and methotrexate.

"Neuromyelitis Optica Spectrum Disorder (NMOSD)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline landscape is provided which includes the disease overview and Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment guidelines. The assessment part of the report embraces, in depth Neuromyelitis Optica Spectrum Disorder (NMOSD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuromyelitis Optica Spectrum Disorder (NMOSD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Neuromyelitis Optica Spectrum Disorder (NMOSD) R&D. The therapies under development are focused on novel approaches to treat/improve Neuromyelitis Optica Spectrum Disorder (NMOSD).

Neuromyelitis Optica Spectrum Disorder (NMOSD) Emerging Drugs Chapters

This segment of the Neuromyelitis Optica Spectrum Disorder (NMOSD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Emerging Drugs

• JYP0061: Guangzhou JOYO Pharma Co., Ltd.

JYP0061 is an investigational drug being developed by Guangzhou JOYO Pharma Co., Ltd. for the treatment of acute neuromyelitis optica spectrum disorder (NMOSD). The drug is being evaluated in an open-label, multicenter Phase II study in patients with acute NMOSD who are AQP4-IgG positive. In the study, JYP0061 is administered orally and is being evaluated as a low-dose regimen in combination with reduced-dose or standard-dose glucocorticoids, as well as a high-dose regimen. The study is designed to assess the efficacy and safety of JYP0061, with clinical recovery based on the Expanded Disability Status Scale (EDSS) among the efficacy assessments. Currently, the drug is in Phase II stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

• CE211NS21: CORESTEMCHEMON

CE211NS21 is an allogeneic bone-marrow-derived mesenchymal stem cell (MSC)-based therapy being developed by CORESTEMCHEMON for neuromyelitis optica spectrum disorder (NMOSD). The therapy is administered as an injection and is being investigated in patients with AQP4-IgG-positive NMOSD relapse. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

Further product details are provided in the report……..

Neuromyelitis Optica Spectrum Disorder (NMOSD): Therapeutic Assessment

This segment of the report provides insights about the different Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Neuromyelitis Optica Spectrum Disorder (NMOSD)

There are approx. 11+ key companies which are developing the therapies Neuromyelitis Optica Spectrum Disorder (NMOSD). The companies which have their Neuromyelitis Optica Spectrum Disorder (NMOSD) drug candidates in the most advanced stage, i.e. Phase II include, Guangzhou JOYO Pharma Co., Ltd. and others.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuromyelitis Optica Spectrum Disorder (NMOSD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuromyelitis Optica Spectrum Disorder (NMOSD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Insights

• Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs?
• How many Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuromyelitis Optica Spectrum Disorder (NMOSD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neuromyelitis Optica Spectrum Disorder (NMOSD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Guangzhou JOYO Pharma Co., Ltd.
• CORESTEMCHEMON
• Dragonfly Therapeutics
• Shanghai Pharmaceuticals Holding Co., Ltd.

Key Products

• JYP0061
• CE211NS21
• DF-2511
• B001